Get the Daily Brief
Latest Biotech News
Guardant, Zephyr AI partner—multimodal data to accelerate biomarker discovery
Guardant Health struck a strategic partnership with Zephyr AI to combine Guardant’s large multimodal molecular datasets with Zephyr’s AI and machine learning platform to accelerate discovery of...
Hybrid gRNAs improve adenine base editing—better on‑target edits, lower off‑targets
A University of Pennsylvania team reported that hybrid guide RNAs—gRNAs with select DNA nucleotide substitutions—boost adenine base editor (ABE) performance by reducing off‑target and bystander...
Novartis buys Avidity for $12B – RNA delivery play expands neuroscience portfolio
Novartis agreed to acquire Avidity Biosciences in a deal valued at roughly $12 billion to add three late‑stage antibody‑oligonucleotide conjugate (AOC) programs and a proprietary muscle‑delivery...
Intellia halts two CRISPR trials after severe liver event: enrollment paused
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its in vivo CRISPR program (nex‑z) after a trial volunteer was hospitalized with life‑threatening liver toxicity. The...
GSK acquires Empirico siRNA for COPD – $85M upfront, broad respiratory ambitions
GSK struck a deal to license EMP‑012, an Empirico‑discovered small‑interfering RNA (siRNA) in Phase 1 for chronic obstructive pulmonary disease (COPD), paying $85 million upfront with potential...
Lilly and Nvidia to build pharma’s most powerful supercomputer – AI for drug discovery
Eli Lilly and Nvidia announced a partnership to build what they described as the most powerful supercomputer operated by a pharmaceutical company, aimed at training large AI models for drug...
FDA allows Delix at‑home dosing in next study – non‑hallucinogenic neuroplastogen advances
Delix Therapeutics said early clinical data for its non‑hallucinogenic neuroplastogen showed promise in depression, and the FDA cleared the company to permit at‑home dosing in its upcoming Phase 2...
Zag Bio launches with $80M to engineer thymus‑targeted tolerance medicines
Zag Bio emerged from stealth with $80 million in financing and a platform that aims to induce immune tolerance by delivering bifunctional antibodies to the thymus, the organ that produces...
Hemab raises $157M to pursue coagulation disorder pipeline – sutacimig pivotal next
Hemab Therapeutics closed a $157 million financing to advance a portfolio of programs addressing rare coagulation disorders, including plans to start a pivotal trial of sutacimig in Glanzmann...
BridgeBio to push for approval after positive limb‑girdle Phase 3 readout
BridgeBio reported an encouraging Phase 3 interim readout for ribitol in limb‑girdle muscular dystrophy type 2I/R9 and said it will meet with the FDA to discuss regulatory plans and potential...
Zenas’ obexelimab drives 95% cut in new MS lesions in mid‑stage trial
Zenas Biopharma reported MoonStone phase‑2 data showing obexelimab, a bifunctional monoclonal antibody, produced a 95% reduction in new gadolinium‑enhancing brain lesions at 12 weeks in relapsing...
GeneDx expands into general pediatrics as exome/genome testing surges
GeneDx announced a commercial push into the general pediatrics market, hiring sales teams and streamlining ordering to capture demand after the American Academy of Pediatrics recommended...
Novartis snaps up Avidity for RNA push: $12B deal bolsters neuromuscular pipeline
Novartis agreed to acquire Avidity Biosciences for about $12 billion, securing three late-stage antibody-oligonucleotide conjugate (AOC) programs targeting neuromuscular diseases and a delivery...
Intellia halts CRISPR trials after liver toxicity — Phase III enrollment paused
Intellia Therapeutics paused enrollment and dosing in two late‑stage clinical trials of its in vivo CRISPR candidate for transthyretin amyloidosis after a study volunteer was hospitalized with...
GSK pays up for Empirico siRNA: $85M upfront to target COPD inflammation
GSK licensed global rights to Empirico’s EMP‑012, an inhaled siRNA in Phase 1 for chronic obstructive pulmonary disease (COPD), paying $85 million upfront with up to ~$745 million in potential...
Lilly and Nvidia to build pharma supercomputer — AI‑first drug discovery drive
Eli Lilly announced a partnership with Nvidia to build what the companies describe as the most powerful supercomputer operated by a pharmaceutical company, intended to train large AI models for...
Zenas antibody cuts MS lesions by 95% in phase 2 MRI readout
Zenas Biopharma reported Phase 2 MoonStone trial results showing obexelimab, a bifunctional monoclonal antibody, reduced new gadolinium‑enhancing brain lesions by 95% over 12 weeks versus placebo...
Electra closes $183M to fund pivotal sHLH trial and expand I&I pipeline
Electra Therapeutics raised $183 million in an oversubscribed Series C to support a global pivotal program for ELA026, its monoclonal antibody targeting SIRP receptors for secondary hemophagocytic...
Hemab raises $157M to scale coagulation disorder pipeline
Hemab Therapeutics closed a $157 million financing to advance multiple programs for bleeding disorders, including a pivotal trial planned for sutacimig in Glanzmann thrombasthenia and an...
GeneDx doubles down on pediatrics: revenue surge and market expansion plan
GeneDx reported Q3 revenue up 52% year‑over‑year, driven by exome and genome test growth, and announced a commercial build‑out targeting the general pediatrics market. The company plans to nearly...